source
- ‘Substantially better than before’: Why India has golden opportunity to build on innovative R&D winsA string of recent wins on the frontiers of novel drug development could mean that a homegrown innovation industry is within reach.
- Merck-Kelun ADC sac-TMT shows progression-free survival benefit with Keytruda in late-stage NSCLC trialKelun-Biotech announced that its antibody‑drug conjugate sac‑TMT, developed with Merck, achieved positive Phase 3 results when paired with Keytruda in a non‑small cell lung cancer trial. The data…